Intellia Therapeutics, Inc. (NASDAQ:NTLA) Given Average Recommendation of “Hold” by Analysts

Intellia Therapeutics, Inc. (NASDAQ:NTLA) has earned a consensus recommendation of “Hold” from the twenty-one research firms that are currently covering the firm, Marketbeat reports. Three equities research analysts have rated the stock with a sell recommendation, nine have assigned a hold recommendation and nine have issued a buy recommendation on the company. The average twelve-month price target among brokerages that have covered the stock in the last year is $18.00.

Several analysts have recently issued reports on the stock. Robert W. Baird set a $7.00 target price on Intellia Therapeutics in a research note on Tuesday, January 27th. JMP Securities reduced their price objective on Intellia Therapeutics from $33.00 to $29.00 and set a “market outperform” rating for the company in a research note on Tuesday, October 28th. Royal Bank Of Canada lowered their target price on Intellia Therapeutics from $14.00 to $9.00 and set a “sector perform” rating on the stock in a research note on Friday, November 7th. JPMorgan Chase & Co. restated an “underweight” rating and set a $5.00 price objective (down previously from $12.00) on shares of Intellia Therapeutics in a report on Friday, November 7th. Finally, Wells Fargo & Company lowered their price objective on shares of Intellia Therapeutics from $17.00 to $12.00 and set an “equal weight” rating on the stock in a research report on Friday, November 7th.

Intellia Therapeutics Stock Up 10.7%

Shares of NASDAQ NTLA opened at $12.28 on Monday. The firm has a market cap of $1.42 billion, a PE ratio of -2.88 and a beta of 2.10. The company’s fifty day simple moving average is $10.82 and its 200 day simple moving average is $12.96. Intellia Therapeutics has a 12-month low of $5.90 and a 12-month high of $28.25.

Intellia Therapeutics (NASDAQ:NTLA) last announced its quarterly earnings results on Thursday, November 6th. The company reported ($0.92) EPS for the quarter, beating analysts’ consensus estimates of ($1.02) by $0.10. Intellia Therapeutics had a negative net margin of 774.94% and a negative return on equity of 57.01%. The business had revenue of $13.78 million during the quarter, compared to analyst estimates of $14.12 million. During the same quarter in the previous year, the business posted ($1.34) EPS. Intellia Therapeutics’s quarterly revenue was up 51.6% on a year-over-year basis. On average, equities analysts predict that Intellia Therapeutics will post -5.07 earnings per share for the current year.

Insiders Place Their Bets

In other Intellia Therapeutics news, CEO John M. Leonard sold 34,146 shares of the business’s stock in a transaction on Monday, January 5th. The shares were sold at an average price of $9.21, for a total transaction of $314,484.66. Following the sale, the chief executive officer owned 1,013,339 shares of the company’s stock, valued at $9,332,852.19. The trade was a 3.26% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP James Basta sold 10,397 shares of the stock in a transaction on Monday, January 5th. The stock was sold at an average price of $9.21, for a total value of $95,756.37. Following the sale, the executive vice president owned 101,528 shares in the company, valued at approximately $935,072.88. This represents a 9.29% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 53,051 shares of company stock worth $488,600 over the last quarter. 3.10% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Intellia Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the stock. Comerica Bank boosted its holdings in Intellia Therapeutics by 45.8% in the 4th quarter. Comerica Bank now owns 2,869 shares of the company’s stock valued at $26,000 after purchasing an additional 901 shares during the period. Headlands Technologies LLC purchased a new position in shares of Intellia Therapeutics in the 2nd quarter worth about $26,000. Blue Bell Private Wealth Management LLC purchased a new stake in Intellia Therapeutics in the third quarter worth approximately $30,000. Caitong International Asset Management Co. Ltd bought a new position in shares of Intellia Therapeutics during the 3rd quarter valued at $30,000. Finally, Whipplewood Advisors LLC grew its stake in shares of Intellia Therapeutics by 114,900.0% during the second quarter. Whipplewood Advisors LLC now owns 3,450 shares of the company’s stock valued at $32,000 after buying an additional 3,447 shares during the last quarter. 88.77% of the stock is currently owned by institutional investors.

About Intellia Therapeutics

Intellia Therapeutics, Inc (NASDAQ: NTLA) is a clinical‐stage biotechnology company focused on developing potentially curative genome editing therapies using the CRISPR/Cas9 platform. The company’s research spans both in vivo and ex vivo applications of CRISPR/Cas9, aiming to correct or disable disease‐causing genes with a single administration. Intellia’s lead in vivo program targets transthyretin amyloidosis (ATTR) by delivering CRISPR/Cas9 machinery directly to the liver, while additional preclinical efforts pursue treatments for hemophilia A, hereditary angioedema and other genetic disorders.

Beyond its in vivo pipeline, Intellia collaborates with strategic partners to extend the impact of its genome editing approach.